[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ucb Sa ADR (UCBJY)

Ucb Sa ADR (UCBJY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 54,793,120
  • Shares Outstanding, K 378,040
  • Annual Sales, $ 8,758 M
  • Annual Income, $ 1,763 M
  • EBIT $ 0 M
  • EBITDA $ 2,982 M
  • 60-Month Beta 0.46
  • Price/Sales 6.48
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/18/26 [--]
  • Annual Dividend & Yield (Fwd) 0.53 (0.33%)
  • Most Recent Dividend 0.525 on 05/05/26
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
132.9900 +8.99%
on 05/18/26
160.0800 -9.46%
on 06/12/26
+7.8900 (+5.76%)
since 05/15/26
3-Month
130.4100 +11.14%
on 04/29/26
162.2318 -10.66%
on 04/13/26
-1.8700 (-1.27%)
since 03/16/26
52-Week
89.0000 +62.85%
on 06/18/25
168.7600 -14.11%
on 02/18/26
+51.4900 (+55.10%)
since 06/16/25

Most Recent Stories

More News
UCB SA (0NZT) Gets a Buy from Berenberg Bank

In a report released yesterday, from Berenberg Bank maintained a Buy rating on UCB SA, with a price target of €290.00. The company’s shares closed yesterday at €258.30.Elevate Your Investing Strategy:...

UCBJF : 297.1875 (-4.18%)
UCBJY : 144.9400 (-3.43%)
Barclays Keeps Their Buy Rating on UCB SA (0NZT)

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA, with a price target of €270.00. The company’s shares closed last Friday at €257.24.Elevate Your Investing...

UCBJF : 297.1875 (-4.18%)
UCBJY : 144.9400 (-3.43%)
TD Cowen Sticks to Its Buy Rating for UCB SA (0NZT)

TD Cowen analyst Stacy Ku maintained a Buy rating on UCB SA today and set a price target of €300.00. The company’s shares closed yesterday at €257.96.Elevate Your Investing Strategy: Take advantage...

UCBJF : 297.1875 (-4.18%)
UCBJY : 144.9400 (-3.43%)
Deutsche Bank Sticks to Their Buy Rating for UCB SA (0NZT)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on UCB SA today and set a price target of €285.00. The company’s shares closed last Friday at €250.10.Elevate Your Investing Strategy:...

UCBJF : 297.1875 (-4.18%)
UCBJY : 144.9400 (-3.43%)
Goldman Sachs Remains a Buy on UCB SA (0NZT)

Goldman Sachs analyst Rajan Sharma reiterated a Buy rating on UCB SA on September 29 and set a price target of €255.00. The company’s shares closed yesterday at €244.62.Elevate Your Investing Strategy:...

UCBJF : 297.1875 (-4.18%)
UCBJY : 144.9400 (-3.43%)
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

ATLANTA , Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX...

UCB : 33.31 (-0.42%)
UCBJY : 144.9400 (-3.43%)
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

ATLANTA , Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX ® (bimekizumab-bkzx) in adults...

UCB : 33.31 (-0.42%)
UCBJY : 144.9400 (-3.43%)
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

ATLANTA , Sept. 10, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today shared results from the "Rheum for Improvement" survey that sought to further understand unmet...

UCB : 33.31 (-0.42%)
UCBJY : 144.9400 (-3.43%)
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

BRUSSELS , Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy...

UCB : 33.31 (-0.42%)
UCBJF : 297.1875 (-4.18%)
UCBJY : 144.9400 (-3.43%)
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment

ATLANTA , Aug. 5, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion...

UCB : 33.31 (-0.42%)
UCBJY : 144.9400 (-3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson's disease. It also provides therapy in the areas of oncology, immunology, inflammation,...

See More

Key Turning Points

3rd Resistance Point 149.0357
2nd Resistance Point 148.0897
1st Resistance Point 146.5149
Last Price 144.9400
1st Support Level 143.9941
2nd Support Level 143.0481
3rd Support Level 141.4733

See More

52-Week High 168.7600
Last Price 144.9400
Fibonacci 61.8% 138.2917
Fibonacci 50% 128.8800
Fibonacci 38.2% 119.4683
52-Week Low 89.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.